Alkacel is often combined with other agents as part of a multi-drug regimen for multiple myeloma or ovarian cancer. Combination protocols are determined by the oncology team to optimise efficacy while managing overlapping toxicities.
Fever may indicate neutropenic infection, a serious complication of myelosuppression. Contact your oncology care team immediately; they may advise prompt evaluation and possible empirical antibiotics.
All melphalan products contain the same active ingredient and share the same mechanism of action. Variations may exist in inactive excipients, tablet appearance, or packaging, but therapeutic effects are equivalent when the same dose is administered.
Melphalan has a plasma half-life of about 1-1.5 hours. However, DNA cross-links it creates may persist for several days, contributing to its prolonged antitumor activity.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of any import restrictions. Some countries may require a customs declaration for controlled chemotherapy agents.
Renal impairment can increase melphalan exposure and the risk of myelosuppression. Dose reduction based on creatinine clearance is recommended, and frequent renal-function monitoring is essential.
In the UK, Alkacel tablets typically bear the imprint “AL-2” identifying the brand and strength. Check the packaging or consult a pharmacist for verification.
Melphalan does not significantly interfere with the efficacy of hormonal contraceptives, but pregnancy must be avoided due to teratogenic risk. Using a reliable non-hormonal method (e.g., barrier) is advisable during treatment.
Live vaccines (e.g., varicella, yellow fever) are contraindicated because melphalan suppresses immune function. Inactivated vaccines may be administered, but timing should be coordinated with the oncology team.
Alkacel is reimbursed under the NHS for approved cancer indications. Prescription charges may apply only in exceptional circumstances; specialist oncology clinics typically arrange dispensing through hospital pharmacies.
Alkacel contains the active ingredient melphalan, an alkylating chemotherapy agent used in oncology. It is available in the United Kingdom as a 2 mg oral pill and is classified under oncology-support medications. Alkacel is a prescription-only product (Rx) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Melphalan belongs to the nitrogen-mustard class of alkylating agents. After oral absorption, it enters the bloodstream and is distributed to rapidly dividing cells. The drug forms covalent bonds with DNA, creating cross-links that interfere with DNA replication and transcription. This damage triggers cell-cycle arrest and ultimately leads to apoptotic death of malignant cells. Onset of action typically occurs within hours of dosing, with a plasma half-life of 1-1.5 hours; however, the therapeutic effect persists because DNA cross-links are not readily repaired.
Alkacel (melphalan) is approved in the UK for:
These indications are based on MHRA-approved labeling and reflect the drug’s ability to target proliferating plasma cells and ovarian tumor cells.
Regular follow-up appointments with the oncology team are essential to assess response, adjust dosing, and manage toxicities.
This article provides educational information about Alkacel and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
